Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback